

10/516705

DT 10/516705 PCT/PTO 02 DEC 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: Based on PCT/JP03/06942
Filed: Intl. Filing 02 JUNE 2003
1st Inventor: Takahito HARA
For: Mutant Androgen Receptor, Cancer Cells Expressing
the Same, A Method of Producing Them and Use
Thereof
Atty. Dkt. No. 3056 USOP

Art Unit: tba
Examiner: tba
Allowed:
Batch:
Paper No.:

Information Disclosure Statement

MAIL STOP PCT
P.O. Box 1450
Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Forms PTO/SB/08A and 08B. A legible copy of each listed reference is herewith being provided to the Examiner.


This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached form PTO/SB/08A be returned in accordance with MPEP §609.

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Respectfully submitted,

Dated: 12/2/04
(847) 383-3372
(847) 383-3391


Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Application Number	Based on PCT/JP03/06942
Filing Date	Int'l Filing 02 JUNE 2003
First Named Inventor	Takahito HARA
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3056 US0P

Best Available Copy

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	Based on PCT/JP03/06942
		Filing Date	Int'l Filing 02 JUNE 2003
		First Named Inventor	Takahito HARA
		Art Unit	tba
		Examiner Name	tba
Sheet 2	of 2	Attorney Docket Number	3056 US0P

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A2	MARIANNE D. SADAR, "Androgen-independent Induction of Prostate-specific Antigen Gene Expression via Cross-talk between the Androgen Receptor and Protein Kinase A Signal Transduction Pathways", J. Biol. Chem., (1999), pp. 7777-7783, Vol. 274, No. 12	
	A3	J. VELDSCHOLTE, "A Mutation in the Ligand Binding Domain of the Androgen Receptor of Human INCaP Cells Affects Steroid Binding Characteristics and Response to Anti-Androgens", Biochem. Biophys. Res. Commun., (1990), pp. 534-540, Vol. 173, No. 2.	
	A4	M-E TAPLIN, et al., "Selection for Androgen Receptor Mutations in Prostate Cancers Treated with Androgen Antagonist", Cancer Research, (1999), pp. 2511-2515, Vol. 59, No. 11.	
	A5	M. MARCELLI, et al., "Amino Acid Substitutions in the Hormone-binding Domain of the Human Androgen Receptor Alter the Stability of the Hormone Receptor Complex", J. Clin. Invest. (1994), pp. 1642-1650, Vol. 94, No. 4	
	A6	JAYA P. GADDIPATI, et al., "Frequent Detection of Codon 877 Mutation in the Androgen Receptor Gene in Advanced Prostate Cancers", Cancer Research, (1994), pp. 2861-2864, Vol. 54, No. 11.	
	A7	KYLLIKKI HAAPALA, et al., "Androgen Receptor Alterations in Prostate Cancer Relapsed During a Combined Androgen Blockade by Orchiectomy and Bicalutamide", Laboratory Investigation, (2001), pp. 1647-1651, Vol. 81, No. 12.	
	A8	JOHN KOKONTIS, et al., "Increased Androgen Receptor Activity and Altered c-myc Expression in Prostate Cancer Cells after Long-Term Androgen Deprivation", Cancer Research, (1994), pp. 1566-1573, Vol. 54.	
	A9	YOSHIHISA UMEKITA, et al., "Human Prostate Tumor Growth in Athymic Mice: Inhibition by Androgens and Stimulation by Finasteride", Proc. Natl. Acad. Sci. USA, (1996), pp. 11802-11807, Vol. 93.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Best Available Copy